Home Featured Page 269

Featured

Latest

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic...

Field Trip Health Ltd. to Commence Trading on the Toronto Stock...

MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use...

Silo Wellness Partners with Mushe Inc. to Establish First Legal Brick...

COMPASS Pathways and Kings College London publish cognition results from COMP360...

Psychedelics: A New Fountain of Youth?

MEC Announces Submission of Listing Statement to the CSE in Coordination...

The Psilocybin vs. Escitalopram Trial – Part 2

Psychedelics and Cannabis ETF Launches on NYSE Arca in First for...

Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure...

EDITOR PICKS

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

Mindset Selects its Lead Clinical Candidate, MSP-1014, a Next Generation Psychedelic...

Field Trip Health Ltd. to Commence Trading on the Toronto Stock...

MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use...

Silo Wellness Partners with Mushe Inc. to Establish First Legal Brick...

COMPASS Pathways and Kings College London publish cognition results from COMP360...

Psychedelics: A New Fountain of Youth?

MEC Announces Submission of Listing Statement to the CSE in Coordination...

The Psilocybin vs. Escitalopram Trial – Part 2

Psychedelics and Cannabis ETF Launches on NYSE Arca in First for...

Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure...

EDITOR PICKS

Psychedelic Philanthropy Is Entering Its Next Phase

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY